- Home
- FNF vs UTHR Comparison
FNF vs UTHR Comparison
Compare FNF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNF
- UTHR
- Stock Information
- Founded
- FNF 1847
- UTHR 1996
- Country
- FNF United States
- UTHR United States
- Employees
- FNF N/A
- UTHR N/A
- Industry
- FNF Specialty Insurers
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- FNF Finance
- UTHR Health Care
- Exchange
- FNF Nasdaq
- UTHR Nasdaq
- Market Cap
- FNF 17.2B
- UTHR 16.2B
- IPO Year
- FNF N/A
- UTHR 1999
- Fundamental
- Price
- FNF $55.57
- UTHR $357.55
- Analyst Decision
- FNF Buy
- UTHR Buy
- Analyst Count
- FNF 6
- UTHR 14
- Target Price
- FNF $59.83
- UTHR $370.86
- AVG Volume (30 Days)
- FNF 972.2K
- UTHR 268.9K
- Earning Date
- FNF 11-06-2024
- UTHR 10-30-2024
- Dividend Yield
- FNF 3.49%
- UTHR N/A
- EPS Growth
- FNF 29.08
- UTHR 25.10
- EPS
- FNF 2.76
- UTHR 22.72
- Revenue
- FNF $13,530,000,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- FNF N/A
- UTHR $26.32
- Revenue Next Year
- FNF $8.75
- UTHR $10.37
- P/E Ratio
- FNF $20.15
- UTHR $15.73
- Revenue Growth
- FNF 23.81
- UTHR 25.04
- 52 Week Low
- FNF $46.85
- UTHR $208.62
- 52 Week High
- FNF $64.83
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- FNF 22.24
- UTHR 41.93
- Support Level
- FNF $59.68
- UTHR $358.82
- Resistance Level
- FNF $60.59
- UTHR $378.27
- Average True Range (ATR)
- FNF 1.16
- UTHR 9.60
- MACD
- FNF -0.64
- UTHR -0.51
- Stochastic Oscillator
- FNF 0.42
- UTHR 5.07
About FNF FNF Group of Fidelity National Financial Inc.
Fidelity National Financial Inc provides title insurance, escrow, and other title-related services. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. Substantially all of the company's revenue is generated in the United States.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.